After quantifying the amount of specific molecules present in peripheral blood, both immune checkpoints directly or indirectly linked to anti-PD1 therapy such as sPD1 (Soluble Programmed Cell Death Protein 1), sPD-L1 (Soluble Programmed Death-Ligand 1), sLAG-3 (Soluble Lymphocyte-Activation Gene 3), and sCTLA4 (Soluble Cytotoxic T-Lymphocyte Antigen 4) and other immune biomarkers such as sCD4 (Soluble CD4), sCD73 (Soluble CD73), and sCD74 (Soluble CD74) we interpreted their predictive values on patient outcome by developing a risk model for tumor progression. Here, CD74 is linked to neoplasm.